The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01F | Monoclonal antibodies and antibody drug conjugates | |
4
|
L01FX | Other monoclonal antibodies | |
5
|
L01FX29 |
| Active Ingredient |
|---|
|
Talquetamab is a immunoglobulin G4 proline, alanine, alanine (IgG4 PAA) bispecific antibody directed against GPRC5D and the CD3 receptor on T Cells. Talquetamab promotes enhanced T cell-mediated cytotoxicity through recruitment of CD3-expressing T cells to GPRC5D-expressing cells. Based on the expression of GPRC5D on plasma cells with minimal to no expression detected on B cells and B cell precursors, talquetamab targets multiple myeloma cells particularly. |
| Document | Type | Information Source | |
|---|---|---|---|
| TALVEY Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.